These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 29016225)

  • 1. ASCO Value Framework Highlights the Relative Value of Treatment Options in Ovarian Cancer.
    Foote J; Secord AA; Liang M; Cohn DE; Jewell E; Havrilesky LJ
    J Oncol Pract; 2017 Dec; 13(12):e1030-e1039. PubMed ID: 29016225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness analysis of dose-dense versus standard intravenous chemotherapy for ovarian cancer: An economic analysis of results from the Gynecologic Oncology Group protocol 262 randomized controlled trial.
    Seagle BL; Shahabi S
    Gynecol Oncol; 2017 Apr; 145(1):9-14. PubMed ID: 28196674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is FDA-Approved Bevacizumab Cost-Effective When Included in the Treatment of Platinum-Resistant Recurrent Ovarian Cancer?
    Chappell NP; Miller CR; Fielden AD; Barnett JC
    J Oncol Pract; 2016 Jul; 12(7):e775-83. PubMed ID: 27246689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Cost-Effectiveness of Bevacizumab in Advanced Ovarian Cancer Using Evidence from the ICON7 Trial.
    Hinde S; Epstein D; Cook A; Embleton A; Perren T; Sculpher M
    Value Health; 2016 Jun; 19(4):431-9. PubMed ID: 27325335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intraperitoneal cisplatin and paclitaxel versus intravenous carboplatin and paclitaxel chemotherapy for Stage III ovarian cancer: a cost-effectiveness analysis.
    Bristow RE; Santillan A; Salani R; Diaz-Montes TP; Giuntoli RL; Meisner BC; Armstrong DK; Frick KD
    Gynecol Oncol; 2007 Sep; 106(3):476-81. PubMed ID: 17688927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paclitaxel: a pharmacoeconomic review of its use in the treatment of ovarian cancer.
    Young M; Plosker GL
    Pharmacoeconomics; 2001; 19(12):1227-59. PubMed ID: 11772158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis.
    Cohn DE; Kim KH; Resnick KE; O'Malley DM; Straughn JM
    J Clin Oncol; 2011 Apr; 29(10):1247-51. PubMed ID: 21383297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost effectiveness of intraperitoneal compared with intravenous chemotherapy for women with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study.
    Havrilesky LJ; Secord AA; Darcy KM; Armstrong DK; Kulasingam S;
    J Clin Oncol; 2008 Sep; 26(25):4144-50. PubMed ID: 18757328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study.
    Wenzel LB; Huang HQ; Armstrong DK; Walker JL; Cella D;
    J Clin Oncol; 2007 Feb; 25(4):437-43. PubMed ID: 17264340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group.
    Markman M; Bundy BN; Alberts DS; Fowler JM; Clark-Pearson DL; Carson LF; Wadler S; Sickel J
    J Clin Oncol; 2001 Feb; 19(4):1001-7. PubMed ID: 11181662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A cost-utility analysis of NRG Oncology/Gynecologic Oncology Group Protocol 218: incorporating prospectively collected quality-of-life scores in an economic model of treatment of ovarian cancer.
    Cohn DE; Barnett JC; Wenzel L; Monk BJ; Burger RA; Straughn JM; Myers ER; Havrilesky LJ
    Gynecol Oncol; 2015 Feb; 136(2):293-9. PubMed ID: 25449568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative Assessment of Clinical Benefit Using the ESMO-Magnitude of Clinical Benefit Scale Version 1.1 and the ASCO Value Framework Net Health Benefit Score.
    Cherny NI; de Vries EGE; Dafni U; Garrett-Mayer E; McKernin SE; Piccart M; Latino NJ; Douillard JY; Schnipper LE; Somerfield MR; Bogaerts J; Karlis D; Zygoura P; Vervita K; Pentheroudakis G; Tabernero J; Zielinski C; Wollins DS; Schilsky RL
    J Clin Oncol; 2019 Feb; 37(4):336-349. PubMed ID: 30707056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Update on Gynecologic Oncology Group (GOG) trials in ovarian cancer.
    Ozols RF
    Cancer Invest; 2004; 22 Suppl 2():11-20. PubMed ID: 15573741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of the cost-effectiveness of paclitaxel as alternative combination therapy for advanced ovarian cancer.
    McGuire W; Neugut AI; Arikian S; Doyle J; Dezii CM
    J Clin Oncol; 1997 Feb; 15(2):640-5. PubMed ID: 9053488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Evolution of Metastatic Colorectal Cancer Clinical Trials: Application of the ASCO Framework for Assessing Value.
    Ezeife DA; Parimi S; Cusano ER; Smith MK; Truong TH; Raissouni S; Lin Y; Monzon JG; Li H; Tam VC; Tang PA
    J Natl Compr Canc Netw; 2017 Aug; 15(8):1005-1013. PubMed ID: 28784862
    [No Abstract]   [Full Text] [Related]  

  • 16. Gynecologic oncology group trials in ovarian carcinoma.
    Ozols RF
    Semin Oncol; 1997 Feb; 24(1 Suppl 2):S2-10-S2-12. PubMed ID: 9045325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost effectiveness of alternative strategies for incorporating bevacizumab into the primary treatment of ovarian cancer.
    Barnett JC; Alvarez Secord A; Cohn DE; Leath CA; Myers ER; Havrilesky LJ
    Cancer; 2013 Oct; 119(20):3653-61. PubMed ID: 23921967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intraperitoneal cisplatin and paclitaxel in ovarian cancer.
    Armstrong DK; Bundy B; Wenzel L; Huang HQ; Baergen R; Lele S; Copeland LJ; Walker JL; Burger RA;
    N Engl J Med; 2006 Jan; 354(1):34-43. PubMed ID: 16394300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. From randomised clinical trials to clinical practice : a pragmatic cost-effectiveness analysis of Paclitaxel in first-line therapy for advanced ovarian cancer.
    Limat S; Woronoff-Lemsi MC; Menat C; Madroszyk-Flandin A; Merrouche Y
    Pharmacoeconomics; 2004; 22(10):633-41. PubMed ID: 15244489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advanced ovarian cancer: a clinical update on first-line treatment, recurrent disease, and new agents.
    Ozols RF
    J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S60-73. PubMed ID: 19780247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.